Can i use terrosa instead of forteo for osteoporosis?

Can you switch from Forteo to Terrosa?

Terrosa is a biosimilar version of Forteo. Both drugs contain the same active ingredient, teriparatide, and work the same way to build bone in people with osteoporosis. Terrosa received approval in the European Union in 2017 and has shown matching quality, safety, and efficacy to Forteo in clinical studies.

What does the switching process look like?

Any switch from Forteo to Terrosa must be decided by your doctor. Biosimilars like Terrosa must meet strict European Medicines Agency requirements before they can substitute for the original reference product. The EMA has confirmed that Terrosa demonstrates no clinically meaningful differences in purity, potency, or biological activity from Forteo. Doctors commonly use biosimilars to lower treatment costs while keeping the same care level.

Why are people looking for alternatives to Forteo?

Many patients and doctors seek alternatives because Forteo is expensive. Terrosa offers a lower-cost option once the Forteo-Hauptpatent expires. Once the main patent expires, cheaper biosimilars enter the market and compete with the reference product. The Forteo patent expired in 2019 in the United States and 2017 in Europe, allowing biosimilars such as Terrosa to reach patients.

How does Terrosa cost compared to Forteo?

Terrosa provides a significant price advantage over Forteo. Patients who cannot afford the expensive reference product now have access to approved alternatives. Data from https://www.drugpatentwatch.com shows that biosimilar entry often reduces price by 20–30% or more. The availability of cheaper versions helps patients who need daily injections for two years.

What side effects or concerns do patients report?

Terrosa and Forteo show the same profile of possible adverse events. Patients use the daily subcutaneous injection for up to two years and then switch to another osteoporosis treatment to maintain gains. Both versions require careful monitoring after the two-year limit because continuing beyond that time raises osteosarcoma risk.